Tenax Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Tenax Therapeutics files an amendment to its S-1 registration statement related to a proposed public offering of common stock, warrants, and pre-funded warrants.
NASDAQ
Tenax Therapeutics aims to raise up to $12 million through a public offering of common stock, warrants, and pre-funded warrants to advance its oral levosimendan (TNX-103) Phase 3 trial for pulmonary hypertension with heart failure and preserved ejection fraction (PH-HFpEF).